Matrixyl (Pal-KTTKS)
Also known as: Palmitoyl Pentapeptide-4, Pal-KTTKS, SYN-COLL
Overview
Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a lipophilic pentapeptide conjugate representing a fragment of the type I procollagen C-propeptide (KTTKS, residues 1-5). The palmitoyl group provides membrane permeability for transdermal delivery. Matrixyl is among the most widely studied and commercially used anti-aging cosmeceutical peptides, with randomized controlled clinical trials demonstrating measurable reductions in wrinkle depth and improvements in skin texture. It works by acting as a matrikine—a matrix-derived signal peptide that feeds back to stimulate extracellular matrix synthesis.
Mechanism of Action
The KTTKS core sequence acts as a matrikine signal by binding to collagen-producing fibroblasts and upregulating expression of collagen I, collagen III, fibronectin, and hyaluronic acid. This signaling occurs via TGF-β receptor-independent pathways, activating downstream MAP kinase and AP-1 transcription factor elements to promote ECM gene expression. The palmitoyl group conjugation (at the N-terminus of lysine) dramatically enhances skin penetration by reducing the peptide's hydrophilicity and facilitating passive diffusion through the stratum corneum.
Potential Benefits
- Clinically demonstrated wrinkle depth reduction
- Collagen I and III synthesis stimulation
- Fibronectin and hyaluronic acid upregulation
- Improved skin texture and firmness
- Well-tolerated with decades of cosmeceutical safety data
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 3% Matrixyl serum 1x daily at night |
| Intermediate | 5% Matrixyl 3000 serum 2x daily |
| Advanced | 8% (Matrixyl Synthe'6 formulations) 2x daily |
| Cycle Duration | Continuous cosmetic use; visible effects at 8-12 weeks |
Palmitoyl pentapeptide-4 (Pal-KTTKS). Gold-standard anti-wrinkle cosmetic peptide.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Topical (serum/cream) Moderate — palmitoyl group enhances skin penetration
Apply to clean, dry skin. Can layer under moisturizer and SPF.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Matrixyl (Pal-KTTKS):
Anti-Wrinkle Trio
Standard cosmetic anti-aging stack. Matrixyl stimulates collagen, GHK-Cu remodels ECM, Argireline smooths expression lines.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store at room temperature, away from light and heat |
|---|
Topical/cosmetic peptide — comes pre-formulated. No reconstitution needed.
Need exact syringe measurements?
Amino Acid Sequence
Palmitoyl-Lys-Thr-Thr-Lys-Ser
Side Effects & Safety
- Extremely well-tolerated topically
- Rare contact sensitization
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store cream/serum at room temperature away from direct sunlight and heat. Refrigeration optional to extend shelf life. |
Synergistic Compounds
The following compounds have been studied alongside Matrixyl (Pal-KTTKS) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.